Patents by Inventor Baoyuan ZHANG

Baoyuan ZHANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DRUG COMBINATION AND USE FOR TREATING TUMORS
    Publication number: 20240082247
    Abstract: The present disclosure relates to the combination of IN10018 and an epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of tumors.
    Type: Application
    Filed: November 6, 2023
    Publication date: March 14, 2024
    Inventors: Baoyuan Zhang, Xuebin Liu, Jiaming Gao, Ping Zhang, Ran Pang, Zaiqi Wang
  • USE OF BI853520 IN CANCER TREATMENT
    Publication number: 20230372340
    Abstract: The present invention relates to a method for treating a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is administered in combination with a KRAS inhibitor or an MEK inhibitor.
    Type: Application
    Filed: July 13, 2023
    Publication date: November 23, 2023
    Inventors: Zaiqi Wang, Jiangwei Zhang, Jun Jiang, Baoyuan Zhang
  • USE OF BI853520 IN CANCER TREATMENT
    Publication number: 20230000867
    Abstract: The present invention relates to a method for treating a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is used, which can be administered alone or in combination with a KRAS inhibitor and/or an MEK inhibitor.
    Type: Application
    Filed: November 27, 2020
    Publication date: January 5, 2023
    Inventors: Zaiqi WANG, Jiangwei ZHANG, Jun JIANG, Baoyuan ZHANG